Robert J Fox

List of Publications by Year
in descending order

143	11,951	87401 40	31191 106
papers	citations	h-index	g-index

146	146	146	11937
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI. Multiple Sclerosis Journal, 2022, 28, 198-205.	1.4	18
2	Long-term safety and efficacy of dimethyl fumarate for up to 13â€‰years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Multiple Sclerosis Journal, 2022, 28, 801-816.	1.4	26
3	Charting a global research strategy for progressive MSâ€”An international progressive MS Alliance proposal. Multiple Sclerosis Journal, 2022, 28, 16-28.	1.4	5
4	Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	32
5	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Multiple Sclerosis Journal, 2022, 28, 1526-1540.	1.4	16
6	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5â€‰years. Multiple Sclerosis Journal, 2022, 28, 1591-1605.	1.4	19
7	DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity â€“ Commentary. Multiple Sclerosis Journal, 2022, 28, 187-188.	1.4	2
8	Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211020.	0.5	4
9	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology, 2022, 269, 5093-5104.	1.8	7
10	A doubleâ€blind, randomized, placeboâ€controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsingâ€remitting multiple sclerosis. Annals of Clinical and Translational Neurology, 2022, 9, 977-987.	1.7	7
11	COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes. Multiple Sclerosis and Related Disorders, 2022, 65, 104028.	0.9	3
12	Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1384-1390.	1.4	13
13	Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1564-1576.	1.4	16
14	New applications for independent activities of daily living in measuring disability in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 97-106.	1.4	5
15	Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 742-754.	1.4	11
16	Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study. Neurology, 2021, 96, e491-e500.	1.5	27
17	Patient Perceptions of FDA Approval. Neurology: Clinical Practice, 2021, 11, 273-279.	0.8	0
18	Importance of incorporating quantitative imaging biomarker technical performance characteristics when estimating treatment effects. Clinical Trials, 2021, 18, 197-206.	0.7	2

#	Article	IF	Citations
19	Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype. Annals of Clinical and Translational Neurology, 2021, 8, 111-118.	1.7	8
20	Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1781-1789.	1.4	4
21	Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2014-2022.	1.4	28
22	A New Way to Identify Promising Therapies for Progressive Multiple Sclerosis. Neurology, 2021, 96, 833-834.	1.5	2
23	Juxtacortical susceptibility changes in progressive multifocal leukoencephalopathy at the grayâ€“white matter junction correlates with iron-enriched macrophages. Multiple Sclerosis Journal, 2021, 27, 135245852199965.	1.4	5
24	Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110108.	0.5	1
25	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study. JAMA Neurology, 2021, 78, 558.	4.5	132
26	How common is active inflammation in progressive multiple sclerosis?. Nature Reviews Neurology, 2021, 17, 463-464.	4.9	1
27	Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurology, 2021, 78, 699.	4.5	225
28	Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, 378-388.	1.5	100
29	Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate. International Journal of MS Care, 2021, 23, 239-244.	0.4	3
30	COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	17
31	Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression. Neurology, 2021, 97, 887-888.	1.5	3
32	Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology, 2021, 97, e1870-e1885.	1.5	168
33	Vitamin D Levels and Visual System Measurements in Progressive Multiple Sclerosis. International Journal of MS Care, 2021, 23, 53-58.	0.4	5
34	NARCOMS and Other Registries in Multiple Sclerosis. International Journal of MS Care, 2021, 23, 276-284.	0.4	12
35	A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis. International Journal of MS Care, 2021, 23, 245-252.	0.4	1
36	Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 747853.	1.1	0

#	Article	IF	Citations
37	Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 1102-1110.	1.4	5
38	Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. Multiple Sclerosis Journal, 2020, 26, 1581-1589.	1.4	13
39	Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101440.	0.9	8
40	Fourteen-year serial MRIs of patients with mild and severe courses of MS. Neurology: Clinical Practice, 2020, 10, e5-e6.	0.8	1
41	Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology, 2020, 95, 436-444.	1.5	100
42	The window of opportunity for treatment of progressive multiple sclerosis. Current Opinion in Neurology, 2020, 33, 262-270.	1.8	27
43	Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 yearsâ€™ follow-up of DEFINE, CONFIRM, and ENDORSE. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642091500.	1.5	47
44	Technology-enabled assessments to enhance multiple sclerosis clinical care and research. Neurology: Clinical Practice, 2020, 10, 222-231.	0.8	12
45	Feast or famine in multiple sclerosis therapeutics. Lancet Neurology, The, 2020, 19, 196-197.	4.9	4
46	Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurology: Clinical Practice, 2020, 10, 510-519.	0.8	17
47	Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. Journal of the Neurological Sciences, 2019, 407, 116498.	0.3	14
48	Vitamin D and MRI measures in progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 276-282.	0.9	11
49	Comprehensive Autopsy Program for Individuals with Multiple Sclerosis. Journal of Visualized Experiments, 2019, , .	0.2	12
50	Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. Multiple Sclerosis and Related Disorders, 2019, 29, 86-93.	0.9	18
51	The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments. Multiple Sclerosis and Related Disorders, 2019, 31, 165-172.	0.9	29
52	A survey of risk tolerance to multiple sclerosis therapies. Neurology, 2019, 92, e1634-e1642.	1.5	14
53	Effect of dimethyl fumarate on lymphocytes in RRMS. Neurology, 2019, 92, e1724-e1738.	1.5	66
54	Demyelinating lesions and progressive MS. Neurology, 2019, 93, 283-284.	1.5	1

#	Article	IF	Citations
55	Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance. Neurology, 2018, 90, 819-820.	1.5	15
56	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, The, 2018, 391, 1263-1273.	6.3	684
57	Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. Multiple Sclerosis Journal, 2018, 24, 579-586.	1.4	24
58	Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 501-511.	1.4	86
59	Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis. Drugs, 2018, 78, 1549-1566.	4.9	36
60	Pseudobulbar affect. Neurology: Clinical Practice, 2018, 8, 472-481.	0.8	10
61	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 846-855.	13.9	201
62	Scan-rescan repeatability and cross-scanner comparability of DTI metrics in healthy subjects in the SPRINT-MS multicenter trial. Magnetic Resonance Imaging, 2018, 53, 105-111.	1.0	28
63	Progressive multifocal leukoencephalopathy with extended natalizumab dosing. Neurology: Clinical Practice, 2018, 8, e12-e14.	0.8	9
64	Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurology: Clinical Practice, 2018, 8, 292-301.	0.8	25
65	Technical Note: Retrospective reduction in systematic differences across scanner changes by accounting for noise floor effects in diffusion tensor imaging. Medical Physics, 2018, 45, 4171-4178.	1.6	5
66	Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurology, The, 2018, 17, 870-884.	4.9	103
67	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple Sclerosis Journal, 2017, 23, 253-265.	1.4	126
68	Quantitative quality assurance in a multicenter HARDI clinical trial at 3 T. Magnetic Resonance Imaging, 2017, 35, 81-90.	1.0	13
69	Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies. Multiple Sclerosis Journal, 2017, 23, 1875-1883.	1.4	77
70	Autologous hematopoietic stem cell transplantation for MS. Neurology, 2017, 88, 2072-2073.	1.5	5
71	Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research, 2017, 6, 313-323.	0.6	13
72	High hypothetical interest in physician-assisted death in multiple sclerosis. Neurology, 2017, 88, 1528-1534.	1.5	25

#	Article	IF	Citations
73	T1â€/T2â€weighted ratio differs in demyelinated cortex in multiple sclerosis. Annals of Neurology, 2017, 82, 635-639.	2.8	82
74	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731771548.	0.5	28
75	Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clinical Therapeutics, 2017, 39, 1671-1679.	1.1	26
76	Perspectives on marijuana use and effectiveness. Neurology: Clinical Practice, 2017, 7, 333-343.	0.8	24
77	Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM. Neurology and Therapy, 2017, 6, 175-187.	1.4	16
78	Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Current Medical Research and Opinion, 2017, 33, 175-183.	0.9	34
79	Measuring Brain Tissue Integrity during 4 Years Using Diffusion Tensor Imaging. American Journal of Neuroradiology, 2017, 38, 31-38.	1.2	20
80	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet, The, 2017, 389, 1357-1366.	6.3	235
81	Dimethyl Fumarate. International Journal of MS Care, 2017, 19, 74-83.	0.4	16
82	Shared Decision Making and Autonomy Among US Participants with Multiple Sclerosis in the NARCOMS Registry. International Journal of MS Care, 2017, 19, 303-312.	0.4	30
83	Correlating Function and Imaging Measures of the Medial Longitudinal Fasciculus. PLoS ONE, 2016, 11, e0147863.	1.1	4
84	Long-term registries. Neurology: Clinical Practice, 2016, 6, 97-99.	0.8	2
85	Characterizing absolute lymphocyte count profiles in dimethyl fumarateâ€“treated patients with MS. Neurology: Clinical Practice, 2016, 6, 220-229.	0.8	91
86	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Multiple Sclerosis and Related Disorders, 2016, 10, 44-52.	0.9	43
87	Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemporary Clinical Trials, 2016, 50, 166-177.	0.8	59
88	Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS. Neurology: Clinical Practice, 2016, 6, 397-408.	0.8	18
89	Refining diagnosis of multiple sclerosis with revised MRI criteria. Lancet Neurology, The, 2016, 15, 238-240.	4.9	1
90	Corrigendum. Neurodegenerative Disease Management, 2016, 6, 178-178.	1.2	50

#	Article	IF	Citations
91	Reassessing the risk of natalizumab-associated PML. Journal of NeuroVirology, 2016, 22, 533-535.	1.0	52
92	Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsingâ€“Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurology and Therapy, 2016, 5, 45-57.	1.4	33
93	Relationship between symptom change, relapse activity and disability progression in multiple sclerosis. Journal of the Neurological Sciences, 2016, 362, 121-126.	0.3	2
94	Progressive Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 785-798.	0.4	8
95	Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. International Journal of MS Care, 2016, 18, 138-146.	0.4	6
96	Efficacy of delayedâ€release dimethyl fumarate in relapsingâ€remitting multiple sclerosis: integrated analysis of the phase 3 trials. Annals of Clinical and Translational Neurology, 2015, 2, 103-118.	1.7	48
97	Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study. Neurology and Therapy, 2015, 4, 137-146.	1.4	36
98	Risk tolerance to MS therapies: Survey results from the NARCOMS registry. Multiple Sclerosis and Related Disorders, 2015, 4, 241-249.	0.9	21
99	Chronic Cerebrospinal Venous Insufficiency. Journal of Ultrasound in Medicine, 2015, 34, 1097-1106.	0.8	6
100	Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurology and Therapy, 2015, 4, 93-104.	1.4	80
101	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology, 2015, 84, 1145-1152.	1.5	63
102	Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurology, The, 2015, 14, 208-223.	4.9	188
103	Disability progression in relapsing MS is more than just lesions: The lesson of fingolimod. Multiple Sclerosis Journal, 2015, 21, 843-844.	1.4	0
104	Progressive MS: from pathophysiology to drug discovery. Multiple Sclerosis Journal, 2015, 21, 1376-1384.	1.4	35
105	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosisâ€“related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clinical Therapeutics, 2015, 37, 2543-2551.	1.1	9
106	Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsingâ€“remitting multiple sclerosis (RRMS). Multiple Sclerosis Journal, 2015, 21, 57-66.	1.4	56
107	Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. International Journal of MS Care, 2015, 17, 236-243.	0.4	47
108	MS disease activity in RESTORE. Neurology, 2014, 82, 1491-1498.	1.5	166

#	Article	IF	Citations
109	Biomarkers for MS. Neurology, 2014, 83, 1488-1489.	1.5	1
110	Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsingâ€“remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current Medical Research and Opinion, 2014, 30, 613-627.	0.9	70
111	Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsingâ€“remitting multiple sclerosis: findings from the CONFIRM study. Multiple Sclerosis Journal, 2014, 20, 253-257.	1.4	40
112	BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Current Medical Research and Opinion, 2014, 30, 251-262.	0.9	99
113	Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. Clinical Therapeutics, 2014, 36, 1958-1971.	1.1	36
114	Identifying the Start of Multiple Sclerosis Injury: A Serial DTI Study. Journal of Neuroimaging, 2014, 24, 569-576.	1.0	21
115	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.5	2,344
116	Risk stratification and mitigation in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 639-649.	0.9	7
117	Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study. Interactive Journal of Medical Research, 2014, 3, e3.	0.6	37
118	In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: Yes. Multiple Sclerosis Journal, 2013, 19, 24-25.	1.4	8
119	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsingâ€“remitting multiple sclerosis: subgroup analyses of the CONFIRM study. Journal of Neurology, 2013, 260, 2286-2296.	1.8	68
120	Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology, 2013, 80, 246-252.	1.5	79
121	Dimethyl fumarate for relapsing MS. Neurology: Clinical Practice, 2013, 3, 249-253.	0.8	6
122	Multiple Sclerosis Treatment. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1092-1099.	0.4	1
123	Treatment Discontinuation and Disease Progression with Injectable Disease-Modifying Therapies. International Journal of MS Care, 2013, 15, 194-201.	0.4	37
124	Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. Multiple Sclerosis Journal, 2012, 18, 1534-1540.	1.4	116
125	Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 1087-1097.	13.9	1,161
126	Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology, 2012, 78, 436-437.	1.5	41

#	Article	IF	Citations
127	Advanced MRI in Multiple Sclerosis: Current Status and Future Challenges. Neurologic Clinics, 2011, 29, 357-380.	0.8	31
128	Chronic cerebrospinal venous insufficiency: A Kuhnian paradigm shift or another fad?. Cmaj, 2011, 183, 1824-1825.	0.9	4
129	MRI IN MULTIPLE SCLEROSIS. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 37-57.	0.4	2
130	B-Cell Depletion with Rituximab in Relapsingâ€“Remitting Multiple Sclerosis. New England Journal of Medicine, 2008, 358, 676-688.	13.9	2,107
131	Picturing Multiple Sclerosis: Conventional and Diffusion Tensor Imaging. Seminars in Neurology, 2008, 28, 453-466.	0.5	46
132	A Preliminary Validation Study of Diffusion Tensor Imaging as a Measure of Functional Brain Injury. Archives of Neurology, 2008, 65, 1179-84.	4.9	31
133	Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Annals of Neurology, 2007, 62, 219-228.	2.8	107
134	Current treatment options in multiple sclerosis. Current Treatment Options in Neurology, 2007, 9, 176-86.	0.7	10
135	Treatment of Susac syndrome with gamma globulin and corticosteroids. Journal of the Neurological Sciences, 2006, 251, 17-22.	0.3	50
136	Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Annals of Neurology, 2006, 59, 478-489.	2.8	748
137	Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.. Cleveland Clinic Journal of Medicine, 2006, 73, 91-102.	0.6	52
138	Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications. Multiple Sclerosis Journal, 2005, 11, 140-145.	1.4	41
139	Should patients with relapsing multiple sclerosis be given a higher dose and frequency of interferon-Î²1a?. Nature Clinical Practice Neurology, 2005, 1, 16-17.	2.7	0
140	Multiple sclerosis: disease markers accelerate progress. Lancet Neurology, The, 2004, 3, 10.	4.9	4
141	New directions in MS therapeutics: vehicles of hope. Trends in Immunology, 2004, 25, 632-636.	2.9	40
142	Aphemia: an isolated disorder of articulation. Clinical Neurology and Neurosurgery, 2001, 103, 123-126.	0.6	40
143	High-dose methylprednisolone to treat multiple sclerosis. , 0, , 418-435.		1